SecBot SecBot
DEFA14A ·Filed May 7, 2026

CPRX

CATALYST PHARMACEUTICALS, INC.
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0001193125-26-210587
Proxy solicitation materials
Actionable Insight ▲ Bullish

The all-cash acquisition at a significant premium provides immediate and certain value for CPRX shareholders. The stock should trade near the deal price with a small spread reflecting closing risk (regulatory, shareholder vote). Monitor the proxy filing and HSR review timeline. The FIRDAPSE patent settlement removes a key overhang, extending IP protection to 2035.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$31.17
T+0 close · May 7, 2026 · via day close
Latest settled
+0.35%
T+20 · $31.28
Vs SPY
−2.78%
α at T+20
Next horizon
T+60
due 4mo ago
  1. T+0 · May 7 $31.17entry
  2. T+1 · 6mo ago −0.06%α −0.89% · $31.15
  3. T+5 · 6mo ago −0.03%α −1.54% · $31.16
  4. T+20 · 6mo ago +0.35%α −2.78% · $31.28
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Catalyst Pharmaceuticals has entered into a definitive agreement to be acquired by Angelini Pharma S.p.A. for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. The transaction, unanimously approved by both boards, is expected to close in Q3 2026 and provides a 28% premium to the 30-day VWAP. Separately, Catalyst resolved all pending FIRDAPSE patent litigation with Hetero, pushing generic entry to no earlier than January 2035.

Key Financial Metrics

Vote
merger approval

Key Facts

  • Acquisition price of $31.50 per share in cash, total equity value ~$4.1 billion
  • 28% premium to 30-day VWAP as of April 22, 2026; 21% premium to unaffected closing price
  • Closing expected in Q3 2026, subject to stockholder approval, HSR, and other conditions
  • All directors and executive officers entered into voting agreements to support the merger
  • Termination fee of ~$155.5 million payable by Catalyst under specified circumstances
  • FIRDAPSE patent litigation with Hetero settled; generic entry no earlier than January 2035
  • Merger not subject to financing condition; Angelini financing via cash and debt with BNP Paribas as coordinator
  • J.P. Morgan provided fairness opinion to Catalyst's board

Financial Impact

Total equity value of approximately $4.1 billion at $31.50 per share cash consideration

share priceenterprise value

Risk Factors

  • Shareholder vote may not be obtained (though insider voting agreements cover a significant block)
  • Regulatory delays or antitrust conditions could push closing beyond Q3 2026 or impose remedies
  • Superior proposal could emerge during the go-shop period, triggering termination fee
  • Integration risk post-close for Angelini as a new U.S. market entrant

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-210587
Document: 0001193125-26-210587-index-headers.html0001193125-26-210587
Document: 0001193125-26-210587-index.html0001193125-26-210587
Document: 0001193125-26-210587.txt0001193125-26-210587

Track record

16 reports on CPRX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
  2. Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
  3. Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
  4. Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
  5. Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
  6. Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
  7. Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
  8. Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
  9. May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
  10. May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026